Skip to main content

Table 7 Comparison of clinical effectiveness between TNF-i with MTX (n = 40) and TNF-i without MTX (n = 9)

From: Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Variables TNF-i without MTX (n = 9) TNF-i with MTX (n = 40) *P value
Cure of ulceration, n (%) 4/9 (44.4%) 21/40 (52.5%) 0.7252
Improvement of ulceration, n (%) 4/9 (44.4%) 23/40 (57.5%) 0.7126
Exacerbation of ulceration, n (%) 2/9 (22.2%) 10/40 (25%) 1.0000
Retention rate of TNF-i, n (%) 7/9 (77.8%) 33/40 (82.5%) 0.6631
Changes of DAIBD (month 0–1 year) 39.4 ± 35.7 44.5 ± 37.8 0.8460
Reduction in concomitant CS dose (month 0–1 year) 1.67 ± 3.53 6.13 ± 17.4 0.9191
CS less than 7.5 mg at year 1, n (%) 9/9 (100%) 36/40 (90.0%) 1.0000
  1. Plus-minus values are means ± standard deviation. *P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease